0
Seres Therapeutics, Inc. Banner Image

Seres Therapeutics, Inc. has reached its limit for free report views

Work for Seres Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Seres Therapeutics, Inc.

  • Ticker MCRB
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Seres Therapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in Cambridge, Massachusetts
Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained BreakthroughMore Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is developing SER-401 in a Phase 1b study in patients with metastatic melanoma, SER-301 for ulcerative colitis and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease.
Seres Therapeutics, Inc.

Most Recent Annual Report

Seres Therapeutics, Inc. MOST RECENT 2020 Annual Report and Form 10K

Report Locked. Seres Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports